Pathology report with ER, PR and HER2 status
oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)
tests per year, UK, once, at initial histopathological diagnosis
“Assess the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status of all invasive breast cancers simultaneously at the time of initial histopathological diagnosis.”
NICE NG101 Early and locally advanced breast cancer, recommendations, 2026-11-06
- Kind of source
- Clinical guideline
- Read on
- 2026-11-06
- Daily check
- Quote found at the source on 2026-11-06
- What to know
- Read from the guideline's own text.
Used in
Kept as evidence; no figure on the platform is computed from it yet.